(RTTNews) - Biopharmaceutical company Bristol Myers Squibb Co. (BMY) said Wednesday that following a routine review of the CheckMate -548 Phase 3 trial by an independent data monitoring committee or ...
BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- Halozyme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results